Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Reiterates Overweight on GoDaddy, Maintains $100 Price Target

Piper Sandler analyst Clarke Jeffries reiterates GoDaddy (NYSE:GDDY) with a Overweight and maintains $100 price target.

byBenzinga Newsdesk

February 10, 2023

1 minute read

Piper Sandler analyst Clarke Jeffries reiterates GoDaddy (NYSE:GDDY) with a Overweight and maintains $100 price target.

Redburn Partners Initiates Coverage On Coinbase Global with Buy Rating

By Benzinga Newsdesk

Today, 9:21 PM

Redburn Partners analyst Nicholas Watts initiates coverage on Coinbase Global (NASDAQ:COIN) with a Buy rating.

COIN

Stephens & Co. Maintains Overweight on BellRing Brands, Raises Price Target to $35

By Benzinga Newsdesk

Today, 9:21 PM

Stephens & Co. analyst Ben Bienvenu maintains BellRing Brands (NYSE:BRBR) with a Overweight and raises the price target from $33 to $35.

BRBR

Renewable Energy Group Q2 Adj. EPS $1.64 Beats $1.32 Estimate, Sales $816.22M Beat $717.86M Estimate

By Bill Haddad

Today, 9:21 PM

Renewable Energy Group (NASDAQ:REGI) reported quarterly earnings of $1.64 per share which beat the analyst consensus estimate of $1.32 by 24.24 percent. This is a 8100 percent increase over earnings of $0.02 per share

REGI

Pliant Therapeutics Q2 EPS $(0.64) Up From $(1.39) YoY, Sales $1.79M Down From $3.60M YoY

By Benzinga Newsdesk

Today, 9:21 PM

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.64) per share. This is a 53.96 percent increase over losses of $(1.39) per share from the same period last year. The company reported $1.79 million in

PLRX

Piper Sandler Reiterates Overweight on GoDaddy, Maintains $100 Price Target

Related Posts

Redburn Partners Initiates Coverage On Coinbase Global with Buy Rating

Stephens & Co. Maintains Overweight on BellRing Brands, Raises Price Target to $35

Renewable Energy Group Q2 Adj. EPS $1.64 Beats $1.32 Estimate, Sales $816.22M Beat $717.86M Estimate

Pliant Therapeutics Q2 EPS $(0.64) Up From $(1.39) YoY, Sales $1.79M Down From $3.60M YoY